Search results for "Drugs"

showing 10 items of 747 documents

Is Ranibizumab effective in stopping loss of vision secondary to Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study.

2011

Purpose: To assess the efficacy and safety of Ranibizumab in the treatment of choroidal neovascularization (CNV) caused by pathologic myopia (PM). Design: Prospective, multicenter, interventional case series. Methods: 40 of 39 consecutive patients with PM and CNV were treated with “on-demand” intravitreal injection of ranibizumab 0.5 mg. Final best-corrected VA (BCVA) and its change from baseline were the main outcome measures. Changes in Optical Coherence Tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results: Mean age was 53 ± 13 years, mean refractive error -13.5 ± 6.5 diopters. Median follow-up was 13.3 ± 2 months (range 12 – 18). Fifteen eyes (37.5%) had pre…

Settore MED/30 - Malattie Apparato Visivopathological myopia choroidal neovascularizaton ranibizumab intraocular injection anti-VEGF drugs.
researchProduct

A national multicentre study on severe paediatric recurrent idiopathic pericarditis treated with IL-1 blockers: appropriateness of the standard of ca…

2020

Recurrent pericarditis (RP) is a rare cause of morbidity in children. Non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids and colchicine are the standard of care in adults. Recently, anakinra has been proven to be effective in patients with steroid-dependence and colchicine resistance.

Settore MED/38 - Pediatria Generale E SpecialisticaRecurrent pericarditis Non-steroidal anti-inflammatory drugscolchicine resistance
researchProduct

Fetal and perinatal desths: drugs exposure duruing pregancy

2009

The presentation of this review will focus attention on the area of pediatric forensic medicine and the importance of through investigation of these deaths not only for the appropriate classification of the cause adn manner of deaths, but for complete documentation of toxicological data and pathological findings wich may provide essential informations about the circumstances surrounding the death and possible contributory mechanism.

Settore MED/43 - Medicina Legaledrugs exposure fetal death toxicological and pathological findings
researchProduct

Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.

2023

Background and ObjectivesRelapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination.MethodsAdult, nonacute patients with RRMS, APQ4-NMOSD, and MOGAD and healthy controls were prospectively recruited at the National Hospital for Neurology and Neurosurgery (L…

Sistema nerviós central - MalaltiesMalalties autoimmunitàries:aminoácidos péptidos y proteínas::proteínas::glicoproteínas::glicoproteínas de membranas::butirofilinas::glicoproteína mielínica del oligodendrocito [COMPUESTOS QUÍMICOS Y DROGAS]:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Myelitis Transverse::Neuromyelitis Optica [DISEASES]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::mielitis transversa::neuromielitis óptica [ENFERMEDADES]:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]Esclerosi múltiple:Amino Acids Peptides and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Butyrophilins::Myelin-Oligodendrocyte Glycoprotein [CHEMICALS AND DRUGS]:Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Imatgeria per ressonància magnèticaNA:diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Neurology (clinical)Neurology
researchProduct

Influence of Social Defeat Stress on the Rewarding Effects of Drugs of Abuse

2021

Social defeatmedicine.medical_specialtyDrugs of abuseStress (linguistics)medicinePsychiatryPsychology
researchProduct

The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societi…

2021

The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of "mutational oncology", presents a great potential to change the oncologic therapeutic scenario, but also some critical aspects need to be underlined. A process governance is mandatory to ensure the genomic testing accuracy and homogeneity, the economic sustainability, and the r…

Societies ScientificGenomic profilingDruggabilityNTRK-FusionsMedical OncologyNeoplasmsMedicineHumansAgnostic biomarkersPrecision MedicineHistology-agnosticTumor histologybusiness.industryAgnostic biomarkers; Agnostic drugs; Histology-agnostic; Homologous recombination deficiency; Microsatellite instability; Mismatch repair deficiency; NTRK-Fusions; Precision oncology; Humans; Italy; Medical Oncology; Precision Medicine; Neoplasms; Societies ScientificScientificPrecision oncologyHematologyPrecision medicineData scienceAgnostic drugsOncologyEconomic sustainabilityItalyAgnostic biomarkerMicrosatellite instabilityPosition paperNeoplasmIdentification (biology)Personalized medicineAgnostic drugNTRK-FusionbusinessSocietiesHomologous recombination deficiencyMismatch repair deficiencyHuman
researchProduct

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

2012

Hepatocellular carcinoma (HCC) is the most common liver cancer, accounting for 90% of primary liver cancers. In the last decade it has become one of the most frequently occurring tumors worldwide and is also considered to be the most lethal of the cancer systems, accounting for approximately one third of all malignancies. Although the clinical diagnosis and management of early-stage HCC has improved significantly, HCC prognosis is still extremely poor. Furthermore, advanced HCC is a highly aggressive tumor with a poor or no response to common therapies. Therefore, new effective and well-tolerated therapy strategies are urgently needed. Targeted therapies have entered the field of anti-neopl…

SorafenibOncologymedicine.medical_specialtyPathologyCarcinoma Hepatocellularmedicine.medical_treatmentReviewsAntineoplastic AgentsDiseasesignal transduction inhibitorsModels BiologicalTargeted therapyInternal medicinemedicineCarcinomacancerAnimalsHumansMolecular Targeted TherapyHCCneoplasmsCause of deathbusiness.industryTherapies InvestigationalLiver NeoplasmsCancerDrugs Investigationalmedicine.diseasetargeted therapyVEGFdigestive system diseasesOncologyHepatocellular carcinomaRas/Raf/MEK/ERKHCC targeted therapy VEGF Ras/Raf/MEK/ERK PI3K/Akt/PTEN/mTOR signal transduction inhibitors cancPI3K/Akt/PTEN/mTORLiver cancerbusinessmedicine.drugSignal Transduction
researchProduct

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

2015

Abstract: Introduction: Angiogenesis is fundamental for tumor development and progression. Hence, anti-angiogenic drugs have been developed to target VEGF and its receptors (VEGFRs). Several tyrosine kinase inhibitors (TKIs) have been developed over the years and others are still under investigation, each anti-VEGFR TKI showing a different cardiotoxic profile. Knowledge of the cardiac side-effects of each drug and the magnitude of their expression and frequency can lead to a specific approach. Areas covered: This work reviews the mechanism of action of anti-VEGFR TKIs and the pathophysiological mechanisms leading to cardiotoxicity, followed by close examination of the most important drugs i…

SorafenibOncologymedicine.medical_specialtymedicine.drug_classSettore MED/06 - Oncologia MedicaAntineoplastic AgentsPharmacologyVandetanibModels BiologicalTyrosine-kinase inhibitorPazopanibchemistry.chemical_compoundInternal medicineRegorafenibNeoplasmsmedicineHumansPharmacology (medical)Molecular Targeted TherapyProtein Kinase Inhibitorstyrosine kinase inhibitor cardiac toxicityNeovascularization PathologicSunitinibbusiness.industryPharmacology. TherapyCancerHeartGeneral MedicineDrugs InvestigationalProtein-Tyrosine Kinasesmedicine.diseaseAxitinibReceptors Vascular Endothelial Growth FactorchemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers

2015

Giorgio Lorenzo Colombo,1 Calogero Cammà,2 Adolfo Francesco Attili,3 Roberto Ganga,4 Giovanni Battista Gaeta,5 Giuseppina Brancaccio,5 Jean Marie Franzini,6 Marco Volpe,6 Giuseppe Turchetti7 1Department of Drug Sciences, University of Pavia, Pavia, Italy; 2Section of Gastroenterology, Di.Bi.M.I.S., University of Palermo, Palermo, Italy; 3Department of Clinical Medicine, University of Rome (La Sapienza) Rome, Italy; 4Clinical Medicine Division, Ospedale Brotzu, Cagliari, Italy; 5Viral Hepatitis Unit, Second University, Naples, Italy; 6Business Integration Partners S.p.A., Milan, Italy; 7Scuola Superiore Sant’Anna, Pisa, Italy Background: Hepatocellular carcinoma (HCC) is…

Sorafenibmedicine.medical_specialtyTherapeutics and Clinical Risk ManagementTare weightTransarterial embolizationToxicology and Pharmaceutics (all)DiseaseDisease costDrugs costInternal medicinedisease costsHealth caremedicineDisease costs; Drugs cost; Sorafenib; Transarterial embolization; Medicine (all); Safety Research; Pharmacology Toxicology and Pharmaceutics (all); Chemical Health and Safety; Pharmacology (medical)Pharmacology (medical)General Pharmacology Toxicology and PharmaceuticsStage (cooking)Original ResearchPharmacologyChemical Health and Safetybusiness.industryDisease costs; drugs cost; sorafenib; transarterial embolizationMortality rateMedicine (all)General MedicineSorafenibmedicine.diseasedigestive system diseasesdisease costs drugs cost transarterial embolization sorafenibHepatocellular carcinomaPharmacology Toxicology and Pharmaceutics (all)businessLiver cancerSafety Researchmedicine.drug
researchProduct

Sample preparation strategies for the determination of psychoactive substances in biological fluids

2020

This review focuses on the existing analytical procedures for the determination of new psychoactive substances (NPS) in biological fluids by chromatographic methods. Direct analysis of samples is scarcely employed and most proposed methodologies include a sample pre-treatment in order to remove matrix interferents and, in some cases, pre-concentrate extracts. Current extraction methods for NPS determination in plasma/serum, urine, and oral fluids have been widely discussed, such as liquid-liquid, solid-phase, and micro extraction approaches, highlighting the advantages and drawbacks of the proposed extraction methodologies. Regarding microextraction approaches, techniques like microextracti…

SorbentLiquid Phase MicroextractionLiquid-Liquid ExtractionClinical Chemistry Tests010402 general chemistry01 natural sciencesBiochemistrySpecimen HandlingAnalytical ChemistryMatrix (chemical analysis)Liquid chromatography–mass spectrometryBiological fluidsHumansSample preparationSolid phase extractionSalivaSolid Phase MicroextractionChromatographyPsychotropic DrugsChromatographyChemistrySolid Phase Extraction010401 analytical chemistryOrganic ChemistryExtraction (chemistry)General MedicineBody Fluids0104 chemical sciencesAnalytical proceduresJournal of Chromatography A
researchProduct